Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

85.97 -0.39 (-0.46%)
Streaming Delayed Price Updated: 9:42 AM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 634,501
Open 86.60
Bid (Size) 85.96 (1)
Ask (Size) 85.99 (2)
Prev. Close 86.36
Today's Range 85.91 - 86.60
52wk Range 57.16 - 89.74
Shares Outstanding 1,253,809,440
Dividend Yield 3.30%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
Is Gilead Sciences a Good Stock to Buy Now?
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward. 
Via The Motley Fool

Performance

YTD
+0.67%
+0.67%
1 Month
+1.02%
+1.02%
3 Month
+5.53%
+5.53%
6 Month
+39.55%
+39.55%
1 Year
+34.83%
+34.83%

More News

Read More
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
Via Investor's Business Daily
Gilead Sciences' Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting
Via Benzinga
Gilead Issues Unexpectedly Bullish Outlook After Cancer Drug Sales Rocket
Via Investor's Business Daily
Mount Gilead, OH Author Publishes Children's Book
Via PR Leap
Earnings Outlook For Gilead Sciences
Via Benzinga
'Risk Of Overheating': 4 Experts On Hot January Jobs Report, How The Fed Will React
Via Benzinga
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
Via Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $400 Today
Via Benzinga
Could Gilead Sciences Stock Help You Become a Millionaire?
Via The Motley Fool
Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?
Via The Motley Fool
Gilead Sciences (GILD) Q4 2022 Earnings Call Transcript
Via The Motley Fool
Why Gilead Sciences Stock Is Trading Higher After Hours
Via Benzinga
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Liposome Drug Delivery Market 2023 in-Depth Analysis, Growth, Size, Future Prospect, Regional Development and Global Outlook 2029
Via SBWire
Exposures COVID-19
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
Via Benzinga
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
These 3 Healthcare Stocks With Over 3% Dividend Yields Are Recommended By Benzinga's Most Accurate Analysts
Via Benzinga
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
From Gilead Sciences, Inc. and Arcellx, Inc.
Via Business Wire
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.